Article
Oncology
G. Curigliano, K. Dunton, M. Rosenlund, M. Janek, J. Cathcart, Y. Liu, P. A. Fasching, H. Iwata
Summary: In the DESTINY-Breast03 clinical trial, trastuzumab deruxtecan (T-DXd) showed superior efficacy and safety compared to trastuzumab emtansine (T-DM1) in patients with HER2-positive metastatic breast cancer. Patient-reported outcomes (PROs) and hospitalization data were analyzed, demonstrating that T-DXd may delay time until health-related quality of life deterioration and resulted in longer time to first hospitalization compared to T-DM1.
ANNALS OF ONCOLOGY
(2023)
Review
Oncology
G. Antonarelli, C. Corti, B. T. Salimbeni, P. Tarantino, P. Zagami, A. Marra, D. Trapani, S. Tolaney, J. Cortes, G. Curigliano
Summary: The introduction of antibody-drug conjugates (ADCs) has greatly impacted the treatment of patients with HER2-positive advanced breast cancer (ABC) in the past decade. ADCs have the ability to deliver toxic chemotherapeutics to tumor sites by utilizing monoclonal antibodies. Two different ADCs, trastuzumab emtansine (T-DM1) and trastuzumab deruxtecan (T-DXd), have already been used in clinical practice for HER2-positive ABC treatment, with T-DXd showing better survival outcomes. However, there is still a clinical controversy regarding treatment decisions and benefits following T-DXd. The field of breast cancer research is rapidly changing with the development of novel ADC formulations, and addressing T-DXd resistance is a priority.
Review
Biochemistry & Molecular Biology
Alice Indini, Erika Rijavec, Francesco Grossi
Summary: The review highlights the significant improvement of HER2-targeted therapies in breast and gastric cancer, as well as their potential application in NSCLC and colorectal cancer, focusing on the pharmacologic characteristics, efficacy, and toxicity profile of T-DXd. The article also discusses the latest clinical trial results of T-DXd in solid tumors and ongoing research on combination therapies.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES
(2021)
Article
Oncology
Hiromichi Nakajima, Kenichi Harano, Tokiko Nakai, Shota Kusuhara, Takehiro Nakao, Chikako Funasaka, Chihiro Kondoh, Nobuaki Matsubara, Yoichi Naito, Ako Hosono, Shuichi Mitsunaga, Genichiro Ishii, Toru Mukohara
Summary: The study found that trastuzumab deruxtecan (T-DXd) demonstrated favorable activity in patients with HER2-positive metastatic breast cancer. Additionally, T-DXd showed meaningful benefit in patients with heterogeneity, reduction, or loss of HER2 expression.
Article
Pharmacology & Pharmacy
Jiangping Yang, Jiaqi Han, Yalan Zhang, Muhelisa Muhetaer, Nianyong Chen, Xi Yan
Summary: Through cost-effectiveness analysis, we found that T-DXd is more cost-effective than T-DM1 for patients with HER2-positive metastatic breast cancer in the US, but not in China at current drug prices.
FRONTIERS IN PHARMACOLOGY
(2022)
Article
Oncology
Shanshan Hu, Yilai Wu, Jiajie Luan, Shuowen Wang, Guorong Fan
Summary: T-DXd demonstrates substantial improvement in HER2-positive metastatic breast cancer, but is not cost-effective compared to T-DM1.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
(2023)
Article
Oncology
Preeti Narayan, Christy L. Osgood, Harpreet Singh, Haw-Jyh Chiu, Tiffany K. Ricks, Edwin Chiu Yuen Chow, Junshan Qiu, Pengfei Song, Jingyu Yu, Frances Namuswe, Maria Guiterrez-Lugo, Sherry Hou, William F. Pierce, Kirsten B. Goldberg, Shenghui Tang, Laleh Amiri-Kordestani, Marc R. Theoret, Richard Pazdur, Julia A. Beaver
Summary: On December 20, 2019, FDA granted accelerated approval to ENHERTU for the treatment of HER2-positive breast cancer based on data from DESTINY-Breast01 study. The confirmed overall response rate in 184 patients was 60.3% with a median duration of response of 14.8 months. Despite the risk of interstitial lung disease, the overall safety and efficacy data supported the accelerated approval for this indication.
CLINICAL CANCER RESEARCH
(2021)
Article
Oncology
Shanu Modi
Summary: The article summarizes the results of the DESTINY-Breast01 study, which showed that T-DXd treatment reduced tumor growth in HER2-positive breast cancer patients, with over 60% of patients experiencing tumor shrinkage or disappearance for nearly 15 months on average.
Review
Oncology
Min-long Chen, Wenjie Yu, Binbin Cui, Yijian Yu, Zhaosheng Ma
Summary: This article reports a case of a female patient with HER2-positive metastatic breast cancer and brain metastases who received pyrotinib and trastuzumab-based systematic therapy after palliative craniocerebral radiotherapy as first-line treatment. During the treatment, the tumor lesions regressed significantly, and chemotherapy drugs were gradually phased out. The patient continued to receive trastuzumab and pyrotinib for HER2-targeted therapy, achieving more than 26 months of progression-free survival with stable disease. Further clinical trials are needed to verify the potential of radiotherapy followed by dual HER2-targeted therapy.
FRONTIERS IN ONCOLOGY
(2023)
Review
Oncology
Alejandro Garcia-Alvarez, Andri Papakonstantinou, Mafalda Oliveira
Summary: Development of brain metastases is a significant event for patients with breast cancer, particularly those with HER2-positive tumors. Advances in targeted therapy against the HER2 receptor have improved management of HER2-positive breast cancer. Despite these improvements, brain metastases continue to be a challenge, highlighting the need for further research and innovative treatment strategies.
Article
Medicine, General & Internal
Fabrice Andre, Yeon Hee Park, Sung-Bae Kim, Toshimi Takano, Seock-Ah Im, Giuliano Borges, Joao Paulo Lima, Sercan Aksoy, Joaquin Gavila Gregori, Michelino De Laurentiis, Giampaolo Bianchini, Rebecca Roylance, Yasuo Miyoshi, Anne Armstrong, Rajni Sinha, Manuel Ruiz Borrego, Elgene Lim, Johannes Ettl, Rinat Yerushalmi, Flora Zagouri, Francois P. Duhoux, Tanja Fehm, Dhiraj Gambhire, Jillian Cathcart, Cai Wu, Changan Chu, Anton Egorov, Ian Krop
Summary: In the DESTINY-Breast02 trial, the efficacy and safety of trastuzumab deruxtecan was compared with the treatment of physician's choice in patients with HER2-positive metastatic breast cancer. The results demonstrated that trastuzumab deruxtecan showed significant superiority in progression-free survival compared to other treatment options, and had a favorable benefit-risk profile.
Article
Medicine, General & Internal
Sara A. Hurvitz, Roberto Hegg, Wei-Pang Chung, Seock-Ah Im, William Jacot, Vinod Ganju, Joanne Wing Yan Chiu, Binghe Xu, Erika Hamilton, Srinivasan Madhusudan, Hiroji Iwata, Sevilay Altintas, Jan-Willem Henning, Giuseppe Curigliano, Jose Manuel Perez-Garcia, Sung-Bae Kim, Vanessa Petry, Chiun-Sheng Huang, Wei Li, Jean-Sebastien Frenel, Silvia Antolin, Winnie Yeo, Giampaolo Bianchini, Sherene Loi, Junji Tsurutani, Anton Egorov, Yali Liu, Jillian Cathcart, Shahid Ashfaque, Javier Cortes
Summary: In the DESTINY-Breast03 trial, trastuzumab deruxtecan showed superior progression-free survival compared to trastuzumab emtansine in patients with HER2-positive metastatic breast cancer. The study aimed to compare the efficacy and safety of trastuzumab deruxtecan versus trastuzumab emtansine. The results demonstrated that trastuzumab deruxtecan had the longest reported median progression-free survival and improved overall survival, reaffirming its role as the standard of care in the second-line setting.
Article
Oncology
Toru Mukohara, Ako Hosono, Sachiyo Mimaki, Akiko Nakayama, Shota Kusuhara, Chikako Funasaka, Takehiro Nakao, Yoko Fukasawa, Chihiro Kondoh, Kenichi Harano, Yoichi Naito, Nobuaki Matsubara, Katsuya Tsuchihara, Takeshi Kuwata
Summary: Mutations in the HER2 gene play a role in resistance to anti-HER2 therapies, but co-occurrence of HER2 mutation and amplification is rare. A breast cancer patient with both HER2 amplification and the L755S mutation displayed clinical resistance to standard trastuzumab or lapatinib therapies, but showed good responses to T-DM1 and T-DXd. Anti-HER2 ADCs may be preferred over conventional therapies for patients with HER2-amplified and comutated tumors.
Article
Oncology
Thibaut Sanglier, Jinjoo Shim, Neil Lamarre, Claudia Pena-Murillo, Vincent Antao, Filippo Montemurro
Summary: This study compared the effectiveness of T-DM1 and LC in the treatment of HER2-positive breast cancer patients with brain metastases. The results showed that T-DM1 was more effective than LC in the real world and had better clinical significance compared to LC.
Article
Oncology
Koichi Goto, Yasushi Goto, Toshio Kubo, Kiichiro Ninomiya, Sang-We Kim, David Planchard, Myung-Ju Ahn, Egbert F. Smit, Adrianus Johannes de Langen, Maurice Perol, Elvire Pons-Tostivint, Silvia Novello, Hidetoshi Hayashi, Junichi Shimizu, Dong-Wan Kim, Chih-Hsi Kuo, James Chih-Hsin Yang, Kaline Pereira, Fu-Chih Cheng, Ayumi Taguchi, Yingkai Cheng, Wenqin Feng, Zenta Tsuchihashi, Pasi A. Janne
Summary: T-DXd demonstrates clinically meaningful responses in patients with previously treated HER2-positive non-small-cell lung cancer, with favorable safety at a dosage of 5.4 mg/kg.
JOURNAL OF CLINICAL ONCOLOGY
(2023)
Article
Oncology
Sherko Kuemmel, Mario Campone, Delphine Loirat, Rafael Lopez Lopez, J. Thaddeus Beck, Michelino De Laurentiis, Seock-Ah Im, Sung-Bae Kim, Ava Kwong, Guenther G. Steger, Esther Zamora Adelantado, Francois P. Duhoux, Richard Greil, Irene Kuter, Yen-Shen Lu, Ariadna Tibau, Mustafa Ozguroglu, Christian W. Scholz, Christian F. Singer, Estela Vega, Pauline Wimberger, Claudio Zamagni, Xuan-Mai Couillebault, Liqiong Fan, Nelson Guerreiro, Jennifer Mataraza, Janna Sand-Dejmek, Arlene Chan
Summary: This phase II study aimed to evaluate the efficacy of lacnotuzumab added to gemcitabine plus carboplatin in patients with advanced triple-negative breast cancer. The results showed that lacnotuzumab + gem-carbo had comparable antitumor activity to gem-carbo alone, but with slightly poorer tolerability.
CLINICAL CANCER RESEARCH
(2022)
Article
Oncology
Yoon Jung Jang, Jae Ho Jeong, Jeong Eun Kim, Jin-Hee Ahn, Kyung Hae Jung, Sung-Bae Kim
Summary: This retrospective cohort study investigated patients with metastatic breast cancer treated with trastuzumab deruxtecan and found that a certain percentage of patients developed interstitial lung disease (ILD). The dominant pattern of ILD was organizing pneumonia, and there was no specific distribution of lung lesions observed. Despite the small number of cases investigated, the incidence of trastuzumab deruxtecan-induced ILD in the Korean population was comparable to previous reports.
JOURNAL OF BREAST CANCER
(2022)
Article
Oncology
Bastien Collomb, Amelie Dubromel, Anne Gaelle Caffin, Chloe Herledan, Virginie Larbre, Amandine Baudouin, Ariane Cerutti, Laurence Couturier, Magali Maire, Lionel Karlin, Delphine Maucort-Boulch, Laure Huot, Stephane Dalle, Emmanuel Bachy, Herve Ghesquieres, Gilles Salles, Sebastien Couraud, Benoit You, Gilles Freyer, Veronique Trillet-Lenoir, Florence Ranchon, Catherine Rioufol
Summary: This study assessed symptoms potentially related to adverse events experienced by cancer outpatients treated with OAAs using patient-reported outcomes (PROs). The results showed that almost three-quarters of the patients reported at least one high-level symptom, with fatigue, various psychological disorders, and general pain being the most commonly experienced symptoms. This study highlights the importance of close coordination between community and hospital health professionals and the integration of patient self-reporting systems in oncology clinical practice.
Article
Oncology
Aurore Carrot, Reza-Thierry Elaidi, Olivier Colomban, Denis Maillet, Michel Tod, Benoit You, Stephane Oudard
Summary: This study analyzed a phase III trial dataset in metastatic prostate cancer patients, demonstrating the significant prognostic value of modeled PSA kinetics parameters assessed using mathematical modeling. The results suggest that these parameters could serve as early prognostic/predictive factors in patients undergoing systemic treatments.
Article
Oncology
Benoit You, Lilian Van Wagensveld, Michel Tod, Gabe S. Sonke, Hugo M. Horlings, R. F. P. M. Kruitwagen, Andreas Du Bois, Frederic Selle, Timothy Perren, Jacobus Pfisterer, Florence Joly, Adrian Cook, Marie Christine Kaminsky, Kerstin Wollschlaeger, Alain Lortholary, Oliver Tome, Alexandra Leary, Gilles Freyer, Maaike Van der Aa, Olivier Colomban
Summary: The likelihood of long-term disease-free survival following first-line treatment in ovarian carcinomas is lower than expected and is associated with disease stage and chemosensitivity.
BRITISH JOURNAL OF CANCER
(2022)
Letter
Oncology
Sora Kang, Sung-Bae Kim
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Alicja Puszkiel, Benoit You, Lea Payen, Jonathan Lopez, Jerome Guitton, Pascal Rousset, Juliette Fontaine, Julien Peron, Denis Maillet, Sophie Tartas, Nathalie Bonnin, Veronique Trillet-Lenoir, Olivier Colomban, Diane Augu-Denechere, Gilles Freyer, Michel Tod
Summary: The objective of this study was to develop a pharmacokinetic-pharmacodynamic (PK-PD) model linking everolimus and sorafenib exposure with biomarker dynamics and progression-free survival (PFS). The study found a correlation between sorafenib plasma exposure and soluble vascular endothelial growth factor receptor 2 (sVEGFR2) dynamics. The simulated dosing schedule of sorafenib 200 mg bid 5 days-on/2 days-off + continuous everolimus 5 mg qd showed a higher median PFS compared to the EVESOR trial.
CANCER CHEMOTHERAPY AND PHARMACOLOGY
(2023)
Article
Oncology
Eleni Karamouza, Rosalind M. M. Glasspool, Caroline Kelly, Liz-Anne Lewsley, Karen Carty, Gunnar B. B. Kristensen, Josee-Lyne Ethier, Tatsuo Kagimura, Nozomu Yanaihara, Sabrina Chiara Cecere, Benoit You, Ingrid A. A. Boere, Eric Pujade-Lauraine, Isabelle Ray-Coquard, Cecile Proust-Lima, Xavier Paoletti
Summary: Cancer antigen 125 (CA-125) is a protein that is present in high concentrations in the blood of patients with specific types of cancer, especially ovarian cancer. This study compared different ways of summarizing CA-125 levels during the first 3 to 6 months of treatment for advanced ovarian cancer, and evaluated their ability to predict overall survival. The results showed that measuring CA-125 levels at 3 months and estimating its decline provided the best prediction of overall survival in these patients.
Review
Public, Environmental & Occupational Health
Joanne Wing Yan Chiu, Soo Chin Lee, James Chung-man Ho, Yeon Hee Park, Ta-Chung Chao, Sung-Bae Kim, Elgene Lim, Ching-Hung Lin, Sherene Loi, Su Ying Low, Lynette Li San Teo, Winnie Yeo, Rebecca Dent
Summary: Trastuzumab deruxtecan (T-DXd), an antibody-drug conjugate targeting HER2, has shown improved outcomes for patients with HER2-positive and HER2-low metastatic breast cancer. Monitoring and managing T-DXd-related adverse events (AEs) is a growing need, and experts from the Asia-Pacific region provided recommendations based on clinical trial evidence and regional healthcare considerations. Proactive monitoring and management are crucial for maximizing the benefits of T-DXd.
Article
Oncology
Pauline Corbaux, Benoit You, Rosalind M. Glasspool, Nozomu Yanaihara, Anna Tinker, Kristina Lindemann, Isabelle L. Ray-Coquard, Mansoor R. Mirza, Fabien Subtil, Olivier Colomban, Julien Peron, Eleni Karamouza, Iain McNeish, Caroline Kelly, Tatsuo Kagimura, Stephen Welch, Liz -Anne Lewsley, Xavier Paoletti, Adrian Cook
Summary: In this study, the prognostic and surrogate values of KELIM in advanced ovarian cancer patients were assessed. The results showed that KELIM was associated with overall survival and progression-free survival. Therefore, KELIM can serve as an independent prognostic biomarker and has important implications for treatment success.
EUROPEAN JOURNAL OF CANCER
(2023)
Article
Oncology
Victoria Depoorter, Katrijn Vanschoenbeek, Lore Decoster, Geert Silversmit, Philip R. Debruyne, Inge De Groof, Dominique Bron, Frank Cornelis, Sylvie Luce, Christian Focan, Vincent Verschaeve, Gwenaelle Debugne, Christine Langenaeken, Heidi Van Den Bulck, Jean-Charles Goeminne, Wesley Teurfs, Guy Jerusalem, Dirk Schrijvers, Benedicte Petit, Marika Rasschaert, Jean-Philippe Praet, Katherine Vandenborre, Harlinde De Schutter, Koen Milisen, Johan Flamaing, Cindy Kenis, Freija Verdoodt, Hans Wildiers
Summary: This study aimed to describe end-of-life care and factors associated with palliative care in older patients with cancer in Belgium. The study found that older patients had frequent hospital admissions and emergency department visits before death, with more than half dying in the hospital. Patients with limitations in function and cognition at cancer diagnosis received less palliative care. These findings highlight the need for optimizing healthcare utilization and equal access to palliative care in older cancer patients.
Article
Oncology
Olivier Tredan, Maud Toulmonde, Christophe Le Tourneau, Laure Montane, Antoine Italiano, Isabelle Ray-Coquard, Christelle de la Fouchardiere, Francois Bertucci, Anthony Goncalves, Carlos Gomez-Roca, Benoit You, Valery Attignon, Sandrine Boyault, Philippe A. Cassier, Armelle Dufresne, Severine Tabone-Eglinger, Alain Viari, Emilie Sohier, Maud Kamal, Gwenael Garin, Jean-Yves Blay, David Perol
Summary: Using a randomized discontinuation design, sorafenib was tested on patients with advanced/metastatic solid tumors harboring sorafenib-targeted genes. Continuing sorafenib when stable disease is achieved improves progression-free rate compared to interruption. Sorafenib has tumor-agnostic efficacy in patients with tumors harboring genomic alterations in PDGFRA/B, VEGF-Rs, Flt-3, KIT, FGFR1 or the RAF/MEK/ERK pathway.
Article
Oncology
Guy Jerusalem, Aleix Prat, Roberto Salgado, Mattea Reinisch, Cristina Saura, Manuel Ruiz-Borrego, Petros Nikolinakos, Felipe Ades, Jeiry Filian, Ning Huang, Antonella Mazzei-Abba, Sara M. Tolaney
Summary: The combination of nivolumab, palbociclib, and anastrozole for neoadjuvant treatment in patients with ER+/HER2- breast cancer showed a high incidence of grade 3/4 hepatotoxicity and treatment discontinuation, indicating that this combination should not be further pursued for the treatment of primary ER+/HER2- breast cancer.
Review
Oncology
Hyehyun Jeong, Sung-Bae Kim
Summary: In recent years, endocrine therapy has regained interest as a neoadjuvant treatment for breast cancer. It can not only shrink tumors but also provide important clinical information on endocrine sensitivity, which is crucial for patient prognostication. Additionally, neoadjuvant endocrine therapy offers an opportunity for early assessment of novel agents' clinical efficacy.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY
(2023)
Article
Oncology
Suthinee Ithimakin, Napa Parinyanitikul, Sung-Bae Kim, Yoon-Sim Yap, Janice Tsang, Inda S. Soong, Yukinori Ozaki, Shinji Ohno, Makiko Ono, Jack Junjie Chan, Hung Chun Skye Cheng, Thitiya Dejthevaporn
Summary: This study examined the disparities in access to breast cancer drugs in various Asian countries. The findings suggest that essential breast cancer drugs are generally accessible in most surveyed territories, but there is a discrepancy in accessing high-cost drugs in Thailand compared to other Asian territories.
JOURNAL OF BREAST CANCER
(2022)
